ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma

ACT001, which is derived from an ancient anti-inflammatory drug, has been shown to cross the blood-brain barrier in preclinical studies and has demonstrated anti-glioblastoma (GBM) activity in clinical trials. However, its pharmacological potential for anti-GBM immune response modulation remains unc...

Descripción completa

Detalles Bibliográficos
Autores principales: Tong, Luqing, Li, Jiabo, Li, Qiuying, Wang, Xuya, Medikonda, Ravi, Zhao, Tianna, Li, Tao, Ma, Haiwen, Yi, Li, Liu, Peidong, Xie, Yang, Choi, John, Yu, Shengping, Lin, Yu, Dong, Jun, Huang, Qiang, Jin, Xun, Lim, Michael, Yang, Xuejun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254983/
https://www.ncbi.nlm.nih.gov/pubmed/32483429
http://dx.doi.org/10.7150/thno.41498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254983/
https://www.ncbi.nlm.nih.gov/pubmed/32483429
http://dx.doi.org/10.7150/thno.41498

Ejemplares similares